Your session is about to expire
← Back to Search
Chemotherapy Combination for Non-Hodgkin's Lymphoma
Study Summary
This trial is studying how well giving pixantrone together with cytarabine, methylprednisolone, and cisplatin works in treating patients with relapsed aggressive non-Hodgkin's lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Find a Location
Who is running the clinical trial?
Media Library
- My cancer worsened only once after responding to chemotherapy.I have a history of lymphoblastic lymphoma or mantle cell lymphoma.My condition did not improve after chemotherapy.My creatinine level is 1.5 mg/dL or lower.My cancer is only in my bone marrow and does not have a measurable tumor.My liver function tests are within the required limits.I am fully active or able to carry out light work.My lymphoma is aggressive and confirmed by a biopsy.I am 18 years old or older.My heart functions well, with no recent heart attacks or severe irregular heartbeats.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
With how many medical clinics is this research being conducted?
"There are 28 sites for this clinical trial, which are situated in Newark, Duarte, Denver and other cities. To limit travel as a participant, it is best to choose the location nearest you."
Are patients being currently enrolled in this trial?
"The clinical trial documented on clinicaltrials.gov is not recruiting patients at this time. This particular study was first advertised on April 1st, 2003 and underwent its most recent update on July 4th, 2009. There are 1791 other active clinical trials that are looking for participants right now."
Is there a considerable risk involved with this treatment?
"This treatment received a safety score of 2 because, while there is some evidence backing its safety, there is no data to support efficacy."
Share this study with friends
Copy Link
Messenger